Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pacira Pharmaceuticals Inc Announces Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint


Thursday, 1 Aug 2013 04:01pm EDT 

Pacira Pharmaceuticals Inc announced that results from its second pivotal, Phase 3 clinical trial assessing the safety and efficacy of EXPAREL (bupivacaine liposome injectable suspension) in intercostal nerve block for posterolateral thoracotomy. The study did not achieve its primary endpoint of a reduction of cumulative pain scores over 72 hours. The 180 patients in this randomized, double-blind study across the U.S., Bulgaria, Georgia, Poland and the Czech Republic received either 266 mg of EXPAREL or placebo. 

Related Company News

Company Quote

84.14
-0.36 -0.43%
11:59am EDT